Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 
ORIGINAL ARTICLE
Ahead of print publication  

Yet another utility for isocitrate dehydrogenase-1: Can it serve as an immunomarker to assess tumor margins in gliomas?


1 Department of Pathology and Laboratory Medicine, All India Institute of Medical Science, Rishikesh, Uttarakhand, India
2 Department of Internal Medicine, Northeast Ohio Medical University, Canton Medical Education Foundation, Ohio, USA
3 Department of Pathology, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India
4 Department of Pathology, Medical Trust Hospital, Kochi, Kerala, India

Correspondence Address:
Shalinee Rao,
Department of Pathology and Laboratory Medicine, All India Institute of Medical Science, Virbhadra Road, Rishikesh - 249 201, Uttarakhand
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_22_17

 > Abstract 


Background: Isocitrate dehydrogenase-1 (IDH1) mutation is now an established early event in gliomagenesis. The ability to detect this mutation by several techniques including immunohistochemistry makes it a significant marker for diagnosing and prognosticating gliomas. This study was done to assess the expression of mutant IDH1 in different grades of gliomas and evaluate its utility in differentiating reactive gliosis from glioma and defining surgical margins of these tumors in the operative specimens.
Materials and Methods: A total of fifty cases including equal number of Grade I, II, III, and IV gliomas and gliosis were included in the study. Formalin-fixed, paraffin-embedded tissue sections from these lesions were immunostained with IDH1 and Ki-67 antibody, and percentage of tumor cells that stained positive with these markers was assessed.
Results: Grades II, III, and IV showed consistent immunopositivity for IDH1. No immunostaining was noted in Grade I glioma and gliosis. Mean Ki-67 labeling index correlated with grades of gliomas with low activity in Grade I and high activity in Grade IV. Individual tumor cells infiltrating into adjacent normal brain parenchyma also stained positive with IDH1 antibody.
Conclusion: Immunostaining for IDH1 mutation can be utilized as a reliable marker in the precise diagnosis of diffuse gliomas and also in objective assessment of surgical margins to differentiate gliomas from gliosis.

Keywords: Glioma, infiltration, isocitrate dehydrogenase-1, surgical margin



How to cite this URL:
Rao S, Rajkumar A, Sundaram S, Joyce ME, Duvuru P. Yet another utility for isocitrate dehydrogenase-1: Can it serve as an immunomarker to assess tumor margins in gliomas?. J Can Res Ther [Epub ahead of print] [cited 2019 Jan 20]. Available from: http://www.cancerjournal.net/preprintarticle.asp?id=244205

.






 

 
Top
 
 
  Search
 
     Search Pubmed for
 
    -  Rao S
    -  Rajkumar A
    -  Sundaram S
    -  Joyce ME
    -  Duvuru P
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  >Abstract
  In this article

 Article Access Statistics
    Viewed141    
    PDF Downloaded2    

Recommend this journal